PDC*line Pharma raises €17.5 million ($20,3M) in Series B2 financing round
New funding includes €11.8M in equity and €5.7M in grants. It completes the €20M B1 round of financing announced in...
B2 cohort (high dose added to anti-PD-1) of the PDC-LUNG-101 trial with PDC*lung01 therapeutic cancer vaccine candidate for non-small cell lung cancer has been opened and first patients were dosed
...
It has been a pleasure and an honor for our CEO Eric Halioua to participate Friday October 8th as a speaker at the EU-Korea Global Vaccine partnership roundtable with Mr Han-koo Yeo, Minister for...
Available now for replay, the interview of PDC*line Pharma 's President & CEO Eric Halioua by journalist of the program « Itinéraires santé » in the TV studio of the French Media group Le Figaro.
...
In replay, the intervention of our CEO Eric Halioua and one of our investors Marc Foidart of the Noshaq fund on Monday May 17th at the "Success stories" program dedicated to the Biotechnology on the...
PDC*line Pharma CEO Eric Halioua and COO/CFO Laurent Levy will be present at the Bio€quity Europe 2021 conference Delivered Digitally May 17 - 19, 2021
! A company presentation made by our CEO on...
We are very pleased to announce that our abstract describing our current phase I/II clinical trial objectives and design with our cancer vaccine PDC*lung01 has been accepted for presentation at the...
Eric Halioua, our CEO, will give a company presentation and be part of the Advances in Immuno-Oncology Panel at the SACHS FORUM 14th Annual European Life Sciences CEO Forum. He will also give a...
We are very pleased to announce the publication in Vaccines of a new article describing the capability of our Engineered PDC*line Vaccine to Prime and Expand Multispecific Viral and Tumor Antigen...
We are pleased to announce that our CEO Eric Halioua will present PDC*line Pharma strategy and innovative vaccinal platform on January 21, 2021 at LINK-J's inaugural Advanced Therapy Showcase in Tokyo...
